Sugi Predict

Sugi Predict / Targets / BMP2K

BMP2K

BMP-2-inducible protein kinase · Q9NSY1 · BMP2K on Sugi Atlas →

21,363 patent compounds predicted against BMP2K, 16,990 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL647221 SCHEMBL647221 0.53 4/20
SCHEMBL461564 SCHEMBL461564 0.40 4/20
Tofacitinib Tofacitinib (SCHEMBL322753) 1.00 2/20
SCHEMBL98692 SCHEMBL98692 0.92 2/20
SCHEMBL100845 SCHEMBL100845 0.80 2/20
SCHEMBL100309 SCHEMBL100309 0.77 2/20
SCHEMBL353500 SCHEMBL353500 0.75 2/20
SCHEMBL101864 SCHEMBL101864 0.74 2/20
SCHEMBL101702 SCHEMBL101702 0.71 2/20
SCHEMBL99685 SCHEMBL99685 0.71 2/20
SCHEMBL100966 SCHEMBL100966 0.70 2/20
SCHEMBL101072 SCHEMBL101072 0.70 2/20
SCHEMBL101686 SCHEMBL101686 0.70 2/20
SCHEMBL103295 SCHEMBL103295 0.68 2/20
SCHEMBL100150 SCHEMBL100150 0.66 2/20
SCHEMBL101800 SCHEMBL101800 0.66 2/20
SCHEMBL102410 SCHEMBL102410 0.66 2/20
SCHEMBL99551 SCHEMBL99551 0.65 2/20
SCHEMBL99828 SCHEMBL99828 0.65 2/20
SCHEMBL100575 SCHEMBL100575 0.65 2/20

Clinical trials — most relevant to BMP2K by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Vitamin D and Carboxy PTH Fragments in Coronary Calcification PHASE4WITHDRAWN
Socket Augmentation Using Atorvastatin With Or Without PRGF (Clinical and Histomorphometric Study) PHASE4COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
The Use of Adhesion Molecule Loaded Hydrogel With Minimally Invasive Surgical Technique in Treatment of Periodontal Intrabony Defect PHASE1/PHASE2COMPLETED
Metformin Repurposing in Oral Submucous Fibrosis: Unveiling In Vitro Signaling Pathways, Progressing to Clinical Trial PHASE1/PHASE2COMPLETED
A Study to Evaluate the Safety and Efficacy of Vactosertib and Imatinib in Patients With Advanced Desmoid Tumor PHASE1/PHASE2COMPLETED
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations PHASE2COMPLETED
First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 PHASE1WITHDRAWN
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) PHASE1COMPLETED
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma PHASE1COMPLETED
Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies nanUNKNOWN
Effect of BMPR-2 Gene Mutations on Hemodynamic Response by Iloprost Inhalation in Pulmonary Arterial Hypertension nanCOMPLETED
Short-term Impact of Cyplexinol® on Self-reported Joint Pain nanCOMPLETED
Role of Novel Biomarkers Associated With In-stent Restenosis After Percutaneous Coronary Intervention nanUNKNOWN
StratosPHere (Non-interventional Study) nanCOMPLETED
The PAH Platform for Deep Phenotyping in Korean Subjects nanUNKNOWN
Genetic and Environmental Characteristics of Primary Pulmonary Hypertension nanCOMPLETED
Assessment of the TGF-beta Pathway and Micro-RNA in Pediatric Pulmonary Arterial Hypertension nanUNKNOWN
Immediate Implants in Maxillary Premolar Region Using Xenograft vs Allograft nanUNKNOWN
Early Regenerative Intervention for Post-Traumatic Osteoarthritis nanUNKNOWN
Therapeutic Irrigation Procedures to Treat Apical Periodontitis nanCOMPLETED
Target of Suv420h1/2 in Hepatocytes nanRECRUITING
Study of Metabolic Modifications in Children With Noonan Syndrome nanCOMPLETED
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches. nanRECRUITING
Importance of Neurogenic Inflammation in the Angiogenic Response of the Dental Pulp as a Defensive Response nanCOMPLETED
Induce XT™ Bone Graft in Foot and Ankle Fusion nanENROLLING_BY_INVITATION
Study of Tissue, Blood, and Urine Samples From Patients With Advanced Prostate Cancer nanUNKNOWN
Screening of Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a BMP2K binder may also engage these)

ProteinNameSimilarity
Q91Z96 — 1.000 Q91Z96 →
A6QP06 — 0.999 A6QP06 →
CDKL5 Cyclin-dependent kinase-like 5 0.999 landscape →
MAP3K13 Mitogen-activated protein kinase kinase kinase 13 0.999 landscape →
Q7TN99 — 0.998 Q7TN99 →
Q2PFD7 — 0.998 Q2PFD7 →
A2RUV4 — 0.997 A2RUV4 →
Q86TC9 — 0.997 Q86TC9 →
B2GUY1 — 0.997 B2GUY1 →
P0C1X8 — 0.997 P0C1X8 →
P06537 — 0.997 P06537 →
Q15154 — 0.997 Q15154 →
A7MBB4 — 0.997 A7MBB4 →
Q9H329 — 0.997 Q9H329 →
Q8C0I4 — 0.997 Q8C0I4 →
Q9JIH7 — 0.997 Q9JIH7 →
F1MH24 — 0.997 F1MH24 →
Q5R8X7 — 0.996 Q5R8X7 →
Q08639 — 0.996 Q08639 →
Q8BYH8 — 0.996 Q8BYH8 →
Q29131 — 0.996 Q29131 →
A0A1L8HFX9 — 0.996 A0A1L8HFX9 →
P97868 — 0.996 P97868 →
F1QIC4 — 0.996 F1QIC4 →
Q6DFV3 — 0.996 Q6DFV3 →
AAK1 AP2-associated protein kinase 1 0.996 landscape →
Q4VYR7 — 0.996 Q4VYR7 →
Q91XT4 — 0.996 Q91XT4 →
O95677 — 0.996 O95677 →
BPTF Nucleosome-remodeling factor subunit BPTF 0.996 landscape →